Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of BMS-986408 with or without nivolumab and ipilimumab in advanced solid tumors
2022-500823-61-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of BMS-986408 in Non-hematologic malignancy, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 2 more (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability. Started Jul 2023; status: completed.
02
Drugs
BMS-986408
03
Conditions
Non-hematologic malignancyhead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2022-500823-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500823-61-00.